Madrigal Pharmaceuticals, Inc.

LSE:0JXI Stock Report

Market Cap: US$6.4b

Madrigal Pharmaceuticals Valuation

Is 0JXI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0JXI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$1.72k
Fair Value
83.9% undervalued intrinsic discount
15
Number of Analysts

Below Fair Value: 0JXI ($275.8) is trading below our estimate of fair value ($1718.27)

Significantly Below Fair Value: 0JXI is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0JXI?

Key metric: As 0JXI barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 0JXI. This is calculated by dividing 0JXI's market cap by their current book value.
What is 0JXI's PB Ratio?
PB Ratio8.2x
BookUS$777.16m
Market CapUS$6.40b

Price to Book Ratio vs Peers

How does 0JXI's PB Ratio compare to its peers?

The above table shows the PB ratio for 0JXI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average6.4x
GNS Genus
2.2x36.9%UK£1.2b
AVCT Avacta Group
4x-2.1%UK£193.9m
SBTX SkinBioTherapeutics
13xn/aUK£38.5m
OXB Oxford Biomedica
6.5x92.5%UK£430.6m
0JXI Madrigal Pharmaceuticals
8.2x59.9%US$6.4b

Price-To-Book vs Peers: 0JXI is expensive based on its Price-To-Book Ratio (8.2x) compared to the peer average (6.4x).

Price to Book Ratio vs Industry

How does 0JXI's PB Ratio compare vs other companies in the GB Biotechs Industry?

4 CompaniesPrice / BookEstimated GrowthMarket Cap
DEST Destiny Pharma
0.3x-15.5%US$5.85m
LLAI LungLife AI
0.4x101.0%US$2.89m
VAL ValiRx
0.3xn/aUS$1.29m
0HMP Bellerophon Therapeutics
0.1xn/aUS$489.31k
No more companies available in this PB range
0JXI 8.2xIndustry Avg. 3.1xNo. of Companies4PB01.63.24.86.48+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 0JXI is expensive based on its Price-To-Book Ratio (8.2x) compared to the UK Biotechs industry average (3.1x).

Price to Book Ratio vs Fair Ratio

What is 0JXI's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0JXI PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio8.2x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 0JXI's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0JXI forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$275.80
US$375.60
+36.2%
22.1%US$530.00US$154.00n/a15
Jan ’26US$314.80
US$373.00
+18.5%
22.2%US$530.00US$155.00n/a15
Dec ’25US$328.23
US$372.20
+13.4%
22.1%US$530.00US$155.00n/a15
Nov ’25US$314.44
US$366.07
+16.4%
23.8%US$530.00US$155.00n/a15
Oct ’25US$210.93
US$362.53
+71.9%
23.1%US$511.00US$150.00n/a15
Sep ’25US$245.23
US$362.53
+47.8%
23.1%US$511.00US$150.00n/a15
Aug ’25US$276.94
US$365.33
+31.9%
22.6%US$507.00US$150.00n/a15
Jul ’25US$278.07
US$365.07
+31.3%
22.6%US$507.00US$150.00n/a15
Jun ’25US$228.18
US$363.86
+59.5%
23.5%US$507.00US$150.00n/a14
May ’25US$205.42
US$377.07
+83.6%
23.0%US$565.00US$150.00n/a14
Apr ’25US$266.85
US$394.54
+47.9%
15.7%US$565.00US$270.00n/a13
Mar ’25US$250.81
US$318.92
+27.2%
18.0%US$407.00US$155.00n/a12
Feb ’25US$222.13
US$321.08
+44.5%
14.0%US$383.00US$204.00n/a12
Jan ’25US$231.32
US$315.92
+36.6%
17.9%US$383.00US$154.00US$314.8012
Dec ’24US$205.00
US$315.92
+54.1%
17.9%US$383.00US$154.00US$328.2312
Nov ’24US$133.26
US$318.25
+138.8%
21.3%US$409.00US$154.00US$314.4412
Oct ’24US$150.68
US$326.83
+116.9%
17.9%US$410.00US$224.00US$210.9312
Sep ’24US$182.05
US$334.64
+83.8%
15.8%US$409.00US$224.00US$245.2311
Aug ’24US$205.85
US$340.82
+65.6%
15.0%US$416.00US$224.00US$276.9411
Jul ’24US$230.00
US$340.82
+48.2%
15.0%US$416.00US$224.00US$278.0711
Jun ’24US$279.00
US$331.17
+18.7%
17.7%US$416.00US$224.00US$228.1812
May ’24US$310.47
US$315.83
+1.7%
18.3%US$414.00US$194.00US$205.4212
Apr ’24US$224.81
US$313.17
+39.3%
17.2%US$390.00US$194.00US$266.8512
Mar ’24US$273.00
US$313.17
+14.7%
17.2%US$390.00US$194.00US$250.8112
Feb ’24US$285.32
US$303.00
+6.2%
18.4%US$390.00US$194.00US$222.1312
Jan ’24US$298.95
US$289.75
-3.1%
16.6%US$375.00US$194.00US$231.3212
Analyst Price Target
Consensus Narrative from 15 Analysts
US$352.78
Fair Value
21.8% undervalued intrinsic discount
15
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/18 18:16
End of Day Share Price 2025/01/17 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Madrigal Pharmaceuticals, Inc. is covered by 22 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Matthew LuchiniBMO Capital Markets Equity Research
Jason ZemanskyBofA Global Research
Alexandria HammondBofA Global Research